Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1706-1716

  Lietz, Ruth ^a   Bayer, Wibke ^a,b   Ontikatze, Teona ^a,b   Johrden, Lena ^a   Tenbusch, Matthias ^a   Bonsmann, Michael Storcksdieck genannt ^a   Überla, Klaus ^a   Dittmer, Ulf ^b   Wildner, Oliver ^a,c  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; CXCL14 CHEMOKINE; ENV ANTIGEN; GAG ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA PLUS RETROVIRUS VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; RETROVIRUS INFECTION; VIRUS LOAD; VIRUS VIRULENCE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CHEMOKINE CCL3; HUMANS; MICE; RETROVIRIDAE INFECTIONS; VIRAL VACCINES;

ADENOVIRIDAE; MUS;

EID: 84857065444     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06244-11     Document Type: Article

References (49)

1. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
2. Bayer W, Schimmer S, Hoffmann D, Dittmer U, Wildner O. 2008. Evaluation of the Friend virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies. Vaccine 26: 716-726.
3. Bayer W, et al. 2010. Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection. J. Virol. 84:1967-1976.
4. Bayer W, et al. 2011. Improved vaccine protection against retrovirus protection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes. Retrovirology 8:75.
5. Bonifaz LC, et al. 2004. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199:815-824.
6. Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB. 2006. Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus Ankara enhances antiviral cellular and humoral immune responses. J. Virol. 80:7676-7687.
7. Chen W, Qin H, Chesebro B, Cheever MA. 1996. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J. Virol. 70:7773-7782.
8. Chesebro B, Wehrly K, Stimpfling J. 1974. Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatibility complex. J. Exp. Med. 140: 1457-1467.
9. Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. 1984. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 312:548-551.
10. Cohen J. 2003. Public health. AIDS vaccine trial produces disappointment and confusion. Science 299:1290-1291.
11. Dittmer U, Brooks DM, Hasenkrug KJ. 1999. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nat. Med. 5:189-193.
12. Dmitriev I, et al. 1998. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72: 9706-9713.
13. Doe B, Selby M, Barnett S, Baenziger J, Walker CM. 1996. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc. Natl. Acad. Sci. U. S. A. 93:8578-8583.
14. Flesch IE, Stober D, Schirmbeck R, Reimann J. 2000. Monocyte inflammatory protein-1α facilitates priming of CD8+ T cell responses to exogenous viral antigen. Int. Immunol. 12:1365-1370.
15. Reference deleted
16. Friend C. 1957. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J. Exp. Med. 105:307-318.
17. Fushimi T, Kojima A, Moore MA, Crystal RG. 2000. Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J. Clin. Invest. 105: 1383-1393.
18. Hasenkrug KJ, Brooks DM, Nishio J, Chesebro B. 1996. Differing T-cell requirements for recombinant retrovirus vaccines. J. Virol. 70:368-372.
19. Hasenkrug KJ, Brooks DM, Robertson MN, Srinivas RV, Chesebro B. 1998. Immunoprotective determinants in friend murine leukemia virus envelope protein. Virology 248:66-73.
20. He S, Wang L, Wu Y, Li D, Zhang Y. 2010. CCL3 and CCL20-recruited dendritic cells modified by melanoma antigen gene-1 induce anti-tumor immunity against gastric cancer ex vivo and in vivo. J. Exp. Clin. Cancer Res. 29:37.
21. Higginbotham JN, Seth P, Blaese RM, Ramsey WJ. 2002. The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum. Gene Ther. 13:129-141.
22. Hoffmann D, et al. 2008. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma. J. Invest. Dermatol. 128:988-998.
23. Iwashiro M, et al. 1993. Multiplicity of virus-encoded helper T-cell epitopes expressed on FBL-3 tumor cells. J. Virol. 67:4533-4542.
24. Kawabata H, et al. 2006. Peptide-induced immune protection of CD8+ T cell-deficient mice against Friend retrovirus-induced disease. Int. Immunol. 18:183-198.
25. Lander MR, Chattopadhyay SK. 1984. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic, and mink cell focusforming viruses. J. Virol. 52:695-698.
26. Letvin NL, et al. 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J. Virol. 78:7490-7497.
27. Lu Y, et al. 1999. Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin. Exp. Immunol. 115:335-341.
28. Menten P, Wuyts A, Van DJ. 2002. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 13:455-481.
29. Mittereder N, March KL, Trapnell BC. 1996. Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70:7498-7509.
30. Miyazawa M, et al. 1995. Immunization with a single T helper cell epitope abrogates Friend virus-induced early erythroid proliferation and prevents late leukemia development. J. Immunol. 155:748-758.
31. Miyazawa M, Nishio J, Chesebro B. 1992. Protection against Friend retrovirus-induced leukemia by recombinant vaccinia viruses expressing the gag gene. J. Virol. 66:4497-4507.
32. Murdoch C, Finn A. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95:3032-3043.
33. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. 1999. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10: 965-976.
34. Nchinda G, et al. 2008. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118:1427-1436.
35. Okada N, et al. 2006. Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector. Cancer Gene Ther. 13: 393-405.
36. Perryman S, Nishio J, Chesebro B. 1991. Complete nucleotide sequence of Friend murine leukemia virus, strain FB29. Nucleic Acids Res. 19:6950.
37. Robertson MN, et al. 1991. Production of monoclonal antibodies reactive with a denatured form of the Friend murine leukemia virus gp70 envelope protein: use in a focal infectivity assay, immunohistochemical studies, electron microscopy and Western blotting. J. Virol. Methods 34:255-271.
38. Ruffini PA, Grodeland G, Fredriksen AB, Bogen B. 2010. Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines. Vaccine 29:191-199.
39. Sallusto F, Lanzavecchia A. 2000. Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol. Rev. 177:134-140.
40. Seaman MS, et al. 2005. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J. Virol. 79:2956-2963.
41. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
42. Sitbon M, Nishio J, Wehrly K, Lodmell D, Chesebro B. 1985. Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses. Virology 141: 110-118.
43. Steinman RM, Banchereau J. 2007. Taking dendritic cells into medicine. Nature 449:419-426.
44. Tan MC, et al. 1997. Mannose receptor-mediated uptake of antigens strongly enhancesHLAclass II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol. 27:2426-2435.
45. Trumpfheller C, et al. 2006. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203:607-617.
46. Wagner R, et al. 2000. Rev.-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum. Gene Ther. 11:2403-2413.
47. Yamano T, Kaneda Y, Huang S, Hiramatsu SH, Hoon DS. 2006. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol. Ther. 13:194-202.
48. Yoon HA, Eo SK. 2007. Differential polarization of immune responses by genetic cotransfer of chemokines changes the protective immunity of DNA vaccine against pseudorabies virus. Immunology 120:182-191.
49. Zlotnik A, Yoshie O. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12:121-127.